How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices
Reviewed 13 sourcesPublished by PepVault
What Zepbound, Wegovy, Ozempic and Foundayo cost in 2026: list prices, NovoCare and LillyDirect self-pay, the $25 savings cards and Medicare's $50 Bridge.

- Last reviewed
- Sources
- 13
- Questions
- 6
- Compounds
- 3
The short answer
Without insurance, Novo Nordisk's NovoCare sells Wegovy pens at $199 a month for a new patient's first two fills, then $349 up to 2.4 mg, and the Wegovy pill from $149, as of November 2026. Lilly's 2026 releases price Zepbound from $299 and Foundayo from $149. With commercial coverage, savings cards go as low as $25. Eligible Medicare Part D members pay $50 through the GLP-1 Bridge.
- Self-pay from the makers, per month: Wegovy pen $199 for a new patient's first two fills, then $349; Wegovy pill from $149; Zepbound from $299; Foundayo from $149.
- Savings cards (as little as $25) are for commercial insurance only; Novo Nordisk's cap at $100 a month.
- Medicare's GLP-1 Bridge: $50 a month for Foundayo, Wegovy or the Zepbound KwikPen, July 2026 to December 2027, for those who meet a BMI path.
- From January 1, 2027, Novo Nordisk's list price for Wegovy 2.4 mg and Ozempic falls to $675 a month; self-pay prices don't change.
Evidence: Price and program pages, not clinical trials: Novo Nordisk's NovoCare pages, CMS and Medicare.gov, read on November 20, 2026, and the makers' and the White House's dated releases and fact sheets.

How much does a GLP-1 cost without insurance?
Two prices matter. The list price is what the maker charges before any discount or rebate; most people with coverage don't pay it, but costs tied to a high deductible or coinsurance often follow it511. The self-pay price is what the maker charges you directly, through Lilly's LillyDirect pharmacy or Novo Nordisk's NovoCare home delivery, with a prescription and no insurance involved14. Novo Nordisk's prices below were read on its NovoCare pages on November 20, 2026. Lilly's are the starting prices in its own dated press releases; Lilly lists today's price for every dose on LillyDirect.
| Brand and form | List price, per month | Self-pay price, per month, by dose |
|---|---|---|
| Zepbound KwikPen or vial (Lilly) | $1,088, as the White House gave it on February 5, 202613 | From $299 at the 2.5 mg starting dose, the same for the KwikPen and the vials, as of February 23, 20261; higher doses cost more, and LillyDirect lists each one |
| Mounjaro pen (Lilly) | Lilly lists it on its pricing site | Lilly said on November 6, 2025 that it would add Mounjaro to LillyDirect for self-pay patients3; LillyDirect lists the current price |
| Foundayo tablets (Lilly) | Lilly lists it on its pricing site | From $149 at the lowest dose, as of April 9, 20262; LillyDirect lists each dose's price |
| Wegovy pen (Novo Nordisk) | $1,349.025 | 0.25 and 0.5 mg $199 for a new patient's first two fills, then $349 for 0.25 to 2.4 mg4 |
| Wegovy HD pen, 7.2 mg | $1,349.025 | $3994 |
| Wegovy pill | $1,349.025 | 1.5 mg $149; 4 mg $199; 9 and 25 mg $2994 |
| Ozempic pen (Novo Nordisk) | $1,027.517 | 0.25 and 0.5 mg $199 for a new patient's first two fills, then $349 for 0.25 to 1 mg; 2 mg $4996 |
The cheapest month is rarely the one you stay on. Lilly notes that Zepbound 2.5 mg is a starting dose, not an approved maintenance dose; the maintenance doses are 5, 10 or 15 mg1. A starting price is the price of the first step, and higher doses cost more. On Wegovy, the $199 covers only a new patient's first two fills at 0.25 and 0.5 mg; after that, every pen dose up to 2.4 mg is $3494.
PepVault reminds you on dose day and counts the doses left in your pen or vials, so you can see the next refill coming. Set reminders in PepVault

Is there a Zepbound or Wegovy coupon?
Yes, from the makers, and which one fits depends on your insurance. The savings cards are for commercial insurance, the kind that comes from an employer or a marketplace plan246. Novo Nordisk excludes anyone on Medicare, Medigap, Medicaid, TRICARE, the VA, the DOD or another government program, and for its offer it counts federal employee (FEHB), marketplace and state employee plans as commercial46.
| Brand | Your plan covers it | Your plan doesn't cover it |
|---|---|---|
| Zepbound and Mounjaro | Lilly's savings cards; the current terms and caps are on Lilly's Zepbound and Mounjaro sites | LillyDirect's self-pay prices13 |
| Foundayo | As little as $25 a month, as of April 9, 20262 | The self-pay prices above2 |
| Wegovy and Ozempic | As little as $25 a month; savings capped at $100 a month46 | The self-pay prices above46 |
Read the cap before counting on $25. The cap is the most the card pays in a month, so if your plan leaves you $400 to pay, a $100 cap leaves you $300. Self-pay through NovoCare sits outside insurance: it doesn't count toward your deductible or out-of-pocket maximum4.
Does Medicare cover GLP-1s for weight loss?
Yes, for now, through a temporary program run by CMS, the agency that runs Medicare. The Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027 and charges eligible Part D members a flat $50 copay for a month of Foundayo, Wegovy (pen or tablets) or the Zepbound KwikPen when it is prescribed for weight89. Zepbound's single-dose vials and pens are not in it910. The $50 doesn't count toward the Part D deductible or the yearly out-of-pocket limit, and Extra Help, Medicare's low-income subsidy, can't lower it810.
To qualify you must be 18 or older and meet one of three body mass index paths (BMI, weight measured against height) when treatment starts910:
- BMI 35 or higher.
- BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure as CMS defines it, or chronic kidney disease stage 3a or beyond.
- BMI 27 or higher with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease (narrowed leg arteries that cause pain).
People with type 2 diabetes, moderate to severe obstructive sleep apnea or noncirrhotic MASH (fatty liver disease with inflammation) are not in the Bridge, and neither is anyone whose Part D plan already covers their GLP-1: Medicare sends them to their regular Part D plan, which can cover a GLP-1 for those conditions910.
- Ask your prescriber whether you qualify and which of the three drugs fits you.
- Your prescriber sends the prescription to a pharmacy and certifies that you are using the drug alongside a diet and exercise program10.
- The pharmacy checks your eligibility; it may ask for your Medicare number or the last four digits of your Social Security number10.
- Your prescriber submits the prior authorization, Medicare's approval request, when asked910.
- You pay $50 for each month's supply. The approval holds through December 31, 2027, dose changes included, unless you switch to a different GLP-110.
Questions go to 1-800-MEDICARE (1-800-633-4227)10. What comes after 2027 is open: CMS extended the Bridge through 2027 partly to gather data ahead of a possible BALANCE model in Part D, which is not launching in 20278.
What is TrumpRx, and is it cheaper?
TrumpRx.gov is the federal site, launched on February 5, 2026, through which patients can get brand medicines at discounts in line with the lowest prices paid in other developed nations, which the government calls most-favored-nation prices13. The White House's launch fact sheet put Ozempic and the Wegovy pen as low as $199 a month (an average of $350, by dose) against $1,028 and $1,349, the Wegovy pill as low as $149 against $1,349, and Zepbound as low as $299 (an average of $346) against $1,08813.
Those lowest prices are the same as the makers' own starting self-pay prices in the first table14613. At launch, TrumpRx was a way to reach those prices, not a lower price of its own; TrumpRx.gov lists its current prices.
Will GLP-1 prices drop in 2027?
List prices will for Novo Nordisk's semaglutide brands. From January 1, 2027, the list price of Wegovy 2.4 mg and the 25 mg tablets, Ozempic 0.5, 1 and 2 mg, and Rybelsus 7 and 14 mg falls to $675 a month, about half of Wegovy's current list price11. The company says self-pay prices don't change, so the cut mostly helps people whose costs follow the list price, such as those with a high deductible or coinsurance11.
Medicare's own bill falls too. Under the Medicare Drug Price Negotiation Program, semaglutide (Ozempic, Rybelsus and Wegovy) gets a negotiated price of $274 for a 30-day supply from January 1, 2027, 71% below its 2024 list price of $95912. A month of Wegovy 2.4 mg pens is $385.63 at that price12. That is what Medicare pays the maker, not your copay.
Some self-pay prices end sooner. Novo Nordisk's $199 starter fills run through December 31, 2026, and its pages say pricing will be updated after that date46.
Which way of paying costs you the least?
- Commercial insurance that covers the drug: the maker's savings card, as little as $25 a month within its cap246.
- Commercial insurance that doesn't cover it, or no insurance: the self-pay price through LillyDirect or NovoCare146.
- Medicare Part D, using the drug for weight and meeting a BMI path: the GLP-1 Bridge, $50 a month for Foundayo, Wegovy or the Zepbound KwikPen10.
- Medicare with type 2 diabetes, sleep apnea or MASH: your Part D plan, at its own copay10.
- Medicare or Medicaid but not eligible for the Bridge: Novo Nordisk lets people with government insurance pay its self-pay price, outside their insurance46.
Whichever route you take, the dose and its steps are your prescriber's call; the price follows the dose, not the other way round.
PepVault keeps your weight log and every dose in one place, so the history a prescriber asks for at a renewal is on your phone. Track your weight in PepVault
Sources
- Eli Lilly and Company. Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen (PR Newswire, Feb 23, 2026; read Nov 20, 2026). prnewswire.com
- Eli Lilly and Company. Foundayo (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S. (PR Newswire, Apr 9, 2026; read Nov 20, 2026). prnewswire.com
- Eli Lilly and Company. Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans (PR Newswire, Nov 6, 2025; read Nov 20, 2026). prnewswire.com
- Novo Nordisk. NovoCare: Wegovy savings offer and self-pay prices (offer through Dec 31, 2026; read Nov 20, 2026). novocare.com
- Novo Nordisk. NovoCare: Wegovy list price explained (read Nov 20, 2026). novocare.com
- Novo Nordisk. NovoCare: Ozempic savings offer and self-pay prices (offer through Dec 31, 2026; read Nov 20, 2026). novocare.com
- Novo Nordisk. NovoCare: Ozempic list price (read Nov 20, 2026). novocare.com
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge (page last modified Jul 13, 2026; read Nov 20, 2026). cms.gov
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: information for providers (page last modified Aug 6, 2026; read Nov 20, 2026). cms.gov
- Medicare.gov. Weight loss drugs: the Medicare GLP-1 Bridge (read Nov 20, 2026). medicare.gov
- Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (press release, Feb 24, 2026; read Nov 20, 2026). novonordisk.com
- Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2027 (fact sheet, Nov 2025). cms.gov
- The White House. Fact sheet: President Donald J. Trump launches TrumpRx.gov to bring lower drug prices to American patients (Feb 5, 2026; read Nov 20, 2026). whitehouse.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.